Lantern Pharma (NASDAQ: LTRN) has closed its registered direct offering, generating approximately $4.4 million in gross proceeds through the sale of 2,135,923 shares of common stock or pre-funded warrants at $2.06 per share. The company also issued unregistered warrants in a concurrent private placement to purchase up to 2,135,923 additional shares at $2.27 per share, which could yield up to $4.85 million in additional gross proceeds if fully exercised. This capital infusion is expected to bolster Lantern's precision oncology pipeline and the commercialization of its AI platform.
Lantern Pharma is a clinical-stage precision oncology company that leverages artificial intelligence and machine learning through its proprietary RADR platform to transform cancer therapy development. The company's clinical pipeline includes LP-184, an acylfulvene compound being developed for various solid tumors and, through its wholly owned CNS-focused subsidiary Starlight Therapeutics, for pediatric CNS cancers. Additionally, LP-284 targets hematologic and solid tumors with a TC-NER mechanism, and LP-300, a cisplatin/ethacraplatin analog, is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment.
Beyond its therapeutic pipeline, Lantern has introduced withZeta.ai, a multi-agentic AI co-scientist platform now commercially available as a subscription-based research platform for the global biomedical and drug development community. This platform represents a new revenue stream for the company, diversifying its business model beyond drug development alone. Lantern operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
The closing of this offering provides Lantern with additional financial resources to advance its clinical programs and expand the reach of its AI platform. The company's focus on precision oncology and AI-driven drug discovery positions it at the intersection of two rapidly evolving fields, potentially offering more targeted and effective cancer treatments. As the biomedical industry increasingly adopts AI, Lantern's withZeta.ai platform could become a valuable tool for researchers, further establishing the company's presence in the AI-driven drug development landscape.
For more details on the offering, visit the full press release at https://ibn.fm/Oh6jI. Additional information about Lantern Pharma and its latest updates can be found in the company's newsroom at https://ibn.fm/LTRN.
